Takeda Pharmaceutical Company Limited
4502
Rang in aandelen
#378
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Aandeelprijs
$40.26
Marktkapitalisatie
$64.06B
Verandering (1 dag)
0.71%
Verandering (1 jaar)
42.44%
Land
JP
Handel Takeda Pharmaceutical Company Limited (4502)
Categorie
Healthcare
P/B-ratio voor Takeda Pharmaceutical Company Limited (4502)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Takeda Pharmaceutical Company Limited is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Takeda Pharmaceutical Company Limited van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| 5.041 | - |
IN
|
|
| - | - |
CN
|
